Etravirine NEW
| Price | $68 | $113 | $198 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Etravirine | CAS No.: 269055-15-4 |
| Purity: 99.56% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Etravirine |
| Description | Etravirine (R165335) is a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor. Etravirine is designed to be active against HIV isolates with mutations that confer resistance to the two most commonly prescribed first-generation NNRTIs. It can bind the enzyme reverse transcriptase (RT) in multiple conformations, both for native and mutant RT, thereby blocking the enzymatic activity of RT. |
| In vitro | Etravirine (TMC125), is highly active against wild-type HIV-1 with EC50 of 1.4 nM to 4.8 nM and shows some activity against HIV-2 with EC50 of 3.5 μM. TMC125 also inhibits a series of HIV-1 group M subtypes and circulating recombinant forms and a group O virus. [1] [2] |
| In vivo | Etravirine (TMC125) demonstrates a high genetic barrier against resistance development and remains effective against HIV strains resistant to existing non-nucleoside reverse transcriptase inhibitors (NNRTIs), including those also resistant to protease inhibitors (PIs). Its tolerability profile, assessed in phase IIb trials with treatment-experienced patients, is comparable to the control group[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 50 mg/mL (114.87 mM) |
| Keywords | TMC 125 | Reverse Transcriptase | R 165335 | Inhibitor | Etravirine | HIV | Human immunodeficiency virus | TMC-125 | inhibit | R-165335 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Kaempferol | Dextran sulfate sodium salt (MW 4500-5500) | Lamivudine | Decanedioic acid |
| Related Compound Libraries | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | EMA Approved Drug Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $150.00/1kg |
VIP1Y
|
Hebei Zhuanglai Chemical Trading Co Ltd
|
2024-12-25 | |
| $5.00/1KG |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-22 | |
| $0.00/10G |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2024-07-16 | |
| $50.00/1kg |
Anhui Ruihan Technology Co., Ltd
|
2023-09-06 | ||
| $20.00/1kg |
Hebei Brisk New Material Technology Co. , Ltd.
|
2023-06-05 | ||
| $4.00/1KG |
Wuhan Boyuan Import & Export Co., LTD
|
2023-05-30 | ||
| $150.00/1KG |
Weijer International Trade (Hebei) Co., Ltd
|
2023-03-15 | ||
| $100.00/1g |
Shijiazhuang Gantuo Biotechnology Co., Ltd
|
2023-03-09 | ||
| $200.00/1kg |
Hebei Mingeng Biotechnology Co., Ltd
|
2022-11-21 | ||
| $0.00/25kg |
Zhejiang Hengkang Pharmaceutical Co., Ltd.
|
2022-09-02 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY